Literature DB >> 18391487

Treatment options in Alzheimer's disease: maximizing benefit, managing expectations.

Martin R Farlow1, Michael L Miller, Vojislav Pejovic.   

Abstract

Alzheimer's disease (AD) is becoming an increasingly heavy burden on the society of developed countries, and physicians now face the challenge of providing efficient treatment regimens to an ever-higher number of individuals affected by the disease. Currently approved anti-AD therapies - the cholinesterase inhibitors and the N-methyl-D-aspartate receptor antagonist memantine - offer modest symptomatic relief, which can be enhanced using combination therapy with both classes of drugs. Additionally, alternative therapies such as nonsteroidal anti-inflammatory drugs, vitamin E, selegiline, Ginkgo biloba extracts, estrogens, and statins, as well as behavioral and lifestyle changes, have been explored as therapeutic options. Until a therapy is developed that can prevent or reverse the disease, the optimal goal for effective AD management is to develop a treatment regimen that will yield maximum benefits for individual patients across multiple domains, including cognition, daily functioning, and behavior, and to provide realistic expectations for patients and caregivers throughout the course of the disease. This review provides a basic overview of approved AD therapies, discusses some pharmacologic and nonpharmacologic treatment strategies that are currently being investigated, and offers suggestions for optimizing treatment to fit the needs of individual patients. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18391487     DOI: 10.1159/000122962

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  32 in total

1.  When laughing is no joking matter.

Authors:  Roy Yaari; Helle Brand; James D Seward; Anna D Burke; Adam S Fleisher; Jan Dougherty; Pierre N Tariot
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Alone in the home.

Authors:  Roy Yaari; Geri R Hall; Helle Brand; James D Seward; Anna D Burke; Adam S Fleisher; Jan Dougherty; Pierre N Tariot
Journal:  Prim Care Companion CNS Disord       Date:  2012-02-23

3.  Prevention of neurodegenerative damage to the brain in rats in experimental Alzheimer's disease by adaptation to hypoxia.

Authors:  E B Manukhina; A V Goryacheva; I V Barskov; I V Viktorov; A A Guseva; M G Pshennikova; I P Khomenko; S Yu Mashina; D A Pokidyshev; I Yu Malyshev
Journal:  Neurosci Behav Physiol       Date:  2010-07-16

4.  Preserving independence: treatment decisions over 4 years in an elderly woman with cognitive decline.

Authors:  Roy Yaari; Anna D Burke; Helle Brand; James D Seward; Pierre N Tariot
Journal:  Prim Care Companion CNS Disord       Date:  2013-08-29

5.  As time goes by.

Authors:  Roy Yaari; Geri Hall; Helle Brand; Jan Dougherty; Adam S Fleisher; James D Seward; Pierre N Tariot
Journal:  Prim Care Companion CNS Disord       Date:  2013-04-25

6.  Effects of memantine on cerebrospinal fluid biomarkers of neurofibrillary pathology.

Authors:  Lidia Glodzik; Susan De Santi; Kenneth E Rich; Miroslaw Brys; Elizabeth Pirraglia; Rachel Mistur; Remigiusz Switalski; Lisa Mosconi; Martin Sadowski; Henrik Zetterberg; Kaj Blennow; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

7.  Falling down.

Authors:  Roy Yaari; Helle Brand; Jan Dougherty; Anna D Burke; Adam S Fleisher; James D Seward; Pierre N Tariot
Journal:  Prim Care Companion CNS Disord       Date:  2012-04-26

8.  Sedative load among long-term care facility residents with and without dementia: a cross-sectional study.

Authors:  J Simon Bell; Heidi T Taipale; Helena Soini; Kaisu H Pitkälä
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 9.  Pathways to neurodegeneration: mechanistic insights from GWAS in Alzheimer's disease, Parkinson's disease, and related disorders.

Authors:  Vijay K Ramanan; Andrew J Saykin
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

10.  Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam.

Authors:  Kristina Leuner; Christopher Kurz; Giorgio Guidetti; Jean-Marc Orgogozo; Walter E Müller
Journal:  Front Neurosci       Date:  2010-09-07       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.